Ovid Therapeutics Announces Presentations Related to OV101

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
154
Ovid Therapeutics Announces Presentations Related to OV101 Fragile X Syndrome Program at the 16th National Fragile X Foundation (NFXF) International Conference

CINCINNATI, July 11, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced several presentations related to the OV101 Fragile X syndrome program will be given this week at the 16 th NFXF International Fragile X conference taking place in Cincinnati, Ohio from July 11 – 15, 2018.

OV101 is a novel delta (δ)-selective GABA A receptor agonist that targets the disruption of tonic inhibition, a central physiological process of the brain that is thought to be the underlying cause of Fragile X syndrome and other neurodevelopmental disorders. It is believed that OV101 is the first investigational medicine to target the disruption of tonic inhibition.

Details of the presentations are listed below.

Oral presentation

Title: Fragile X Syndrome: Patient Partnership in Clinical Drug Development Session: Industry Updates Date and Time: Thursday, July 12, 2018, 4:30 – 5:30 p.m. CT

Poster presentations

Title: Development of a Conceptual Model to Inform a Clinical Outcome Assessment Strategy in Adolescents and Young Adults with Fragile X Syndrome Poster ID: 294 Date and Time: Friday, July 13, 2018, 3:45 – 7:00 p.m. CT

Title: Clinical Unmet Needs and Burden in Fragile X Syndrome: Results of a Targeted Literature Review Poster ID: 425 Date and Time: Friday, July 13, 2018, 3:45 – 7:00 p.m. CT

Title: A Literature Review of the Economic Burden of Fragile X Syndrome Poster ID: 429 Date and Time: Friday, July 13, 2018, 3:45 – 7:00 p.m. CT About Fragile X Syndrome Fragile X syndrome is the most common inherited form of intellectual disability and autism, with a prevalence of 1 in 3,600 to 4,000 males and 1 in 4,000 to 6,000 females in the United States. Individuals with Fragile X syndrome often have a range of behavioral challenges, such as cognitive impairment, anxiety, mood swings, hyperactivity, attention deficit, poor sleep, self-injury and heightened sensitivity to various stimuli, such as sound. Additionally, individuals with Fragile X syndrome are prone to comorbid medical issues including seizures and sleep disturbance. Fragile X syndrome results from mutations in the FMR1 gene, which blocks expression of the Fragile X Mental Retardation Protein (FMRP), an important protein in GABA synthesis. There are no FDA-approved therapies for Fragile X syndrome, and treatment primarily consists of behavioral interventions and pharmacologic management of symptoms.

In studies of individuals with Fragile X syndrome and in experimental models, extrasynaptic GABA levels are abnormally reduced, and there is also dysregulation of GABA receptors. This ultimately contributes to a decrease in tonic inhibition, causing the brain to become inundated with signals and lose the ability to separate background noise from critical information.

About OV101 OV101 (gaboxadol) is believed to be the only delta (δ)-selective GABAA receptor agonist in development and the first investigational medicine to specifically target the disruption of tonic inhibition, a central physiological process of the brain that is thought to be the underlying cause of certain neurodevelopmental disorders. OV101 has been demonstrated in laboratory studies and animal models to selectively activate the δ-subunit of GABAA receptors, which are found in the extrasynaptic space (outside of the synapse), and thereby impact neuronal activity through tonic inhibition. 

Ovid is developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. In preclinical studies, it was observed that OV101 improved symptoms of Angelman syndrome and Fragile X syndrome. Gaboxadol has previously been tested in over 4,000 patients (with more than 1000 patient-years of exposure) and was observed to have favorable safety and bioavailability profiles. 

The FDA has granted orphan drug and Fast Track designations for OV101 for both the treatment of Angelman syndrome and Fragile X syndrome. The U.S. Patent and Trademark Office has granted Ovid patents directed to methods of treating Angelman syndrome and Fragile X syndrome using OV101. The issued patents expire in 2035.

About Ovid Therapeutics Ovid Therapeutics (NASDAQ: OVID ) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of people with rare neurological disorders. Ovid has a broad pipeline of first-in-class medicines. The company’s lead investigational medicine, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing TAK-935/OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE).

For more information on Ovid, please visit http://www.ovidrx.com/ .

Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding (i) progress, timing, scope and results of clinical trials for Ovid’s product candidates, and (ii) the potential clinical benefit of OV101 to treat patients with Fragile X. You can identify forward-looking statements because they contain words such as “will,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended March 31, 2018 under the caption “Risk Factors.” Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. 

Contacts

Investors: Lora Pike Ovid Therapeutics Inc. Senior Director, Investor Relations & Public Relations lpike@ovidrx.com   Media:  W2O Group Kelly Boothe, Ph.D. +1-415-946-1076 kboothe@w2ogroup.com  
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Margins Hold Firm as Game Revenue Slips Again

Updated Category News Views 123

A game publisher can look tired at the top line and still be doing plenty right underneath the hood. NetEase’s third-quarter 2026 report is that kind of animal: revenue eased, yet costs behaved, profit rebounded from the prior quarter, and the balance sheet remains absurdly well stocked. For investors in NASDAQ:NTES, this was not a clean victory lap. It was a reminder...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
Shanghai Import Expo Draws 4,000 Global Companies Again

Updated Category News Views 175

Shanghai spent last week making a rather pointed commercial argument: China wants to be seen buying, not merely selling. The ninth China International Import Expo, or CIIE, brought together more than 4,000 overseas companies and participants from 162 countries, regions and international organizations. That is a serious gathering by any reasonable measure, even if the...

Continue Reading
Würk's Bryte AI Targets Payroll's Costly Friction Points

Updated Category News Views 104

Payroll mistakes are the sort of paper cuts that suddenly turn into a hospital bill for an employer. Würk’s Nov. 19 launch of Bryte AI goes straight at that ugly reality in cannabis, beverage alcohol, and other heavily regulated workplaces, where a bad time entry, missed document, or misunderstood policy can create a far more expensive mess than ordinary office...

Continue Reading
Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 47

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 37

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Bella Rio's Proposed Preferred B Share Giveaway Plan

Updated Category News Views 46

A founder handing over two million of his own common shares is the sort of detail that makes investors stop stirring their coffee. Bella Rio Consulting, the company behind ROCK'N Vodka and Bella Rio Bourbon, says co-founder and Vice President Andy Roiniotis proposes to contribute 2,000,000 personally held Common shares for reclassification into Preferred Series B shares....

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 166

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading

Top 5 Most Recently Viewed Articles

Alvopetro Energy Ltd. Reports Record Sales Volumes

Updated Category News Views 127

Alvopetro Energy Ltd. Reports Strong Sales Volumes Alvopetro Energy Ltd. has reported commendable sales volumes for June 2025, reaffirming its position in the energy sector. The company, identified by its ticker symbols ALV (on the TSX Venture Exchange) and ALVOF (on the OTCQX), indicated a notable production rate of 2,514 barrels of oil equivalent per day (boepd) based...

Continue Reading
Mannatech Achieves New Stock Milestone with 52-Week High

Updated Category News Views 177

Mannatech Reaches Remarkable Peak in Stock Performance Mannatech, Incorporated (MTEX), a company dedicated to offering global wellness solutions, has recently achieved a noteworthy milestone by reaching a 52-week high with its stock price hitting $13.34. This impressive rise indicates a substantial increase in investor confidence, as the shares have surged by an...

Continue Reading
Exciting Developments Ahead for FAIRWOOD's Second Season

Updated Category News Views 240

FAIRWOOD Returns with a New Season The popular comedy series FAIRWOOD has officially been renewed for a second season, much to the delight of its fans. The show's creators, renowned musical duo Rusty and Clark Fairwood, along with the talented showrunner Bud Schaetzle, are back at the helm to deliver more engaging episodes. With all six episodes of the first season now...

Continue Reading
Celebrating Pioneers in the $6.8 Trillion Wellness Movement

Updated Category News Views 330

Leaders Transforming the Global Wellness Economy The Global Wellness Summit (GWS), renowned for gathering visionaries in the $6.8 trillion wellness economy, recently wrapped up its 19th annual conference held at an upscale venue. This prestigious gathering celebrated outstanding contributions through the Global Wellness Awards, recognizing individuals who have made...

Continue Reading
CRED iQ & TractIQ Push $50B of Data into AI Era

Updated Category News Views 5

AI-Driven Innovation in Self-Storage Market Mark my words, folks, the marriage of data and AI is reshaping industries faster than a stock split on Wall Street. CRED iQ and TractIQ are venturing into this fast-paced union. Just north of Philadelphia, CRED iQ has sealed a deal with TractIQ, a frontrunner in self-storage data solutions, to funnel a cool $50 billion worth of...

Continue Reading